Erin Mistry
Corporate Officer/Principal chez CORMEDIX INC.
Fortune : 55 167 $ au 31/03/2024
Profil
Erin Mistry is currently the Chief Commercial Officer & Senior Vice President at CorMedix, Inc. (since 2023).
Prior to this, Mr. Mistry worked as the Vice President - Market Access at Intarcia Therapeutics, Inc.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CORMEDIX INC.
0,02% | 07/03/2024 | 13 011 ( 0,02% ) | 55 167 $ | 31/03/2024 |
Postes actifs de Erin Mistry
| Sociétés | Poste | Début |
|---|---|---|
| CORMEDIX INC. | Corporate Officer/Principal | 01/01/2020 |
Anciens postes connus de Erin Mistry
| Sociétés | Poste | Fin |
|---|---|---|
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CORMEDIX INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
